What is the Heparin sodium?

Heparin sodium is , while it's Molecular Formula is Unspecified. Heparin sodium salt is used as a blood anti-coagulant. It is also used as an effective inhibitor of mesenchymal cell proliferation. Further, it binds to antithrombin III, which inhibits coagulation proteases. It is used as a major component of serum free media for preventing cell aggregation. It is also used as an anti-cancer agent in in vitro cancer research.

What is the CAS number for Heparin sodium?

The CAS number of Heparin sodium is 9041-08-1.

What is Heparin sodium (9041-08-1) used for?

Reviparin sodium, a second-generation low molecular weight heparin produced fromporcine mucosal heparin, has been introduced for the prevention of deep vein thrombosis andpulmonary embolism following surgery. It has sustained activity and increased bioavailabilityover unfractioned heparin. More noticeably, reviparin shows a pronounced inhibitory effect,both in vitro and in vivo , on smooth muscle cell proliferation which plays a predominant role inrestenosis following angioplasty. Indeed, a lower incidence of restenosis without majorbleeding complications has been reported for reviparin treated patients who successfullyunderwent percutaneous transluminal coronary angioplasty.

Product Class

9041-08-1

Product Name：Heparin Sodium
Molecular Formula：(C12H16NS2Na3)20
Purity：99%
Molecular Weight：

Inquiry

Product Details:

CasNo： 9041-08-1

Molecular Formula： (C12H16NS2Na3)20

Buy High Quality Heparin Sodium ,99% Pure 9041-08-1 Safe Transportation

Molecular Formula:Unspecified
Molecular Weight:
PSA：0.00000
LogP:0.00000

Heparin Sodium(Cas 9041-08-1) Usage

Description	Heparin Sodium, USP is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosamino-glycans having anticoagulant properties.
Uses	HEPARIN SODIUM INJECTION is an anticoagulant indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prophylaxis and treatment of the thromboembolic complications associated with atrial fibrillation Treatment of acute and chronic consumption coagulopathies Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in transfusion, extracorporeal circulation, and dialysis procedures
Others	Heparin sodium may prolong one-stage prothrombin time; when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hr after last intravenous dose or 24 hr after last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

9041-08-1 Relevant articles

Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP

Andrea Leone-Bay, Duncan R Paton, Bruce Variano, Harry Leipold, Theresa Rivera, Judy Miura-Fraboni, Robert A Baughman, Noemi Santiago

Journal of Controlled Release Volume 50, Issues 1–3, 2 January 1998, Pages 41-49

Heparin activity is typically measured by an increase in plasma clotting time using the prothrombin time (PT) and/or the activated partial thromboplastin time (APTT) assays. The therapeutic target range is 1.5–2.5 times baseline [2], which can be obtained easily by titrating the dose and measuring APTT.

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

List of authors. Russell Hull, M.B., B.S., Terry Delmore, M.SC, Edward Genton, M.D., Jack Hirsh, M.D., Michael Gent, M.SC, David Sackett, M.D., M.SC., Dermot McLoughlin, M.B., B.S., and Peter Armstrong, M.D.

, N Engl J Med 1979; 301:855-858

Seven patients on warfarin sodium experienced bleeding complications (of which four were major), as compared with no patients receiving subcutaneous heparin (P<0.005). Thus, adjusted-dose warfarin sodium is more effective than low-dose subcutaneous heparin in preventing recurrent venous thromboembolism, but its use is accompanied by a significant risk of bleeding.

9041-08-1 Downstream products

9005-49-6
heparin

Relevant Products

Neomycin Sulphate
CAS：1405-10-3
Danuglipron
CAS：2230198-02-2
Tirofiban Hcl
CAS：142373-60-2